ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
August 05, 2021China Pharma Holdings, Inc., a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to ...
Pharma Sources Insight January 2025
